



## Circulating Tumor Cells (CTCs)

Guest Editor:

### Prof. Dr. Dario Marchetti

1. Division of Molecular Medicine, Department of Internal Medicine, The University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA
2. Department of Pathology, The University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA
3. Full Member, UNM Comprehensive Cancer Center, Albuquerque, NM 87131, USA

Deadline for manuscript submissions:

**closed (30 November 2018)**

### Message from the Guest Editor

Dear Colleagues,

The major cause of patient mortality in cancer is metastasis; however, understanding of the metastatic cascade and mechanisms underlying this complex set of events remain poorly understood. Because dissemination mostly occurs through the blood, circulating tumor cells (CTCs) are of paramount importance and one of the most promising areas of oncology research. CTCs might serve as “liquid biopsy” as a better way to diagnose cancer patients compared to painful biopsies of the primary tumor. Much of the CTC biology needs to be discovered and many scientific/technical challenges must be overcome before their clinical promise as biomarkers and targets for improved therapies can be fulfilled. The objective of this Special Issue is to publish the latest findings in CTC research and clinical implementation. Contributions outlining CTC discoveries in biological and clinical settings, CTC theoretical and pre-clinical models, CTC technologies and methods for their detection, and clinical findings applying CTC concepts, are welcome.

Prof. Dr. Dario Marchetti  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)